NCT06002828 Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
| NCT ID | NCT06002828 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ECOG-ACRIN Cancer Research Group |
| Condition | Hodgkin Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-10-13 |
| Primary Completion | 2030-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-10-13 with a primary completion date of 2030-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Patient must be \>= 18 years of age at the time of registration * Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL) * Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration * Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration * NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach * Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3 * Patient must be English speaking in order to be able to complete the required QOL forms on this study * NOTE: Sites cannot translate the associated QOL forms * Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma * Patient must have internet access through computer, tablet, or smartphone * Patient must have email address * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Contact & Investigator
Bradley J Zebrack
PRINCIPAL INVESTIGATOR
ECOG-ACRIN Cancer Research Group
Frequently Asked Questions
Who can join the NCT06002828 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hodgkin Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06002828 currently recruiting?
Yes, NCT06002828 is actively recruiting participants. Visit ClinicalTrials.gov or contact ECOG-ACRIN Cancer Research Group to inquire about joining.
Where is the NCT06002828 trial being conducted?
This trial is being conducted at Anchorage, United States, Anchorage, United States, Anchorage, United States, Anchorage, United States and 11 additional locations.
Who is sponsoring the NCT06002828 clinical trial?
NCT06002828 is sponsored by ECOG-ACRIN Cancer Research Group. The principal investigator is Bradley J Zebrack at ECOG-ACRIN Cancer Research Group. The trial plans to enroll 2,000 participants.